A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies (Cancer Immunology Research)

Congrats to the LAVA team for the publication of exciting new data from a bispecific Vγ9Vδ2 T-cell engager directed against CD40 in Cancer Immunology Research.

Link to full publication